Preclinical antitumor activity of CI-973,[SP-4-3-(R)]-[1,1-cyclobutanedicarboxylato(2-)] (2 methyl-1,4-butane-diamine-N,N′)platinum
| Autor: | Alan J. Kraker, Charles W. Moore, William L. Elliott, Wilbur R. Leopold, Billy J. Roberts |
|---|---|
| Rok vydání: | 1991 |
| Předmět: |
Pathology
medicine.medical_specialty medicine.medical_treatment Transplantation Heterologous Cell Drug Resistance Mice Nude Antineoplastic Agents Carboplatin Mice In vivo Tumor Cells Cultured medicine Animals Humans Pharmacology (medical) Pharmacology Cisplatin Chemotherapy Leukemia Experimental business.industry Neoplasms Experimental medicine.disease In vitro Transplantation Leukemia medicine.anatomical_structure Oncology Cell culture Cancer research Drug Screening Assays Antitumor business Cell Division medicine.drug |
| Zdroj: | Investigational New Drugs. 9:1-8 |
| ISSN: | 1573-0646 0167-6997 |
| Popis: | The antitumor activity of [SP-4-3-(R)]-[1,1-cyclobutanedicarboxylato-(2-)](2 methyl-1,4-butanediamine-N,N')platinum (CI-973) was characterized in a number of preclinical model systems. CI-973 retained substantial activity in cisplatin resistant murine leukemia cell lines, in vitro and in vivo; in L1210 leukemia resistant to cisplatin in vivo, CI-973 retained as much activity as was found in animals bearing sensitive L1210 leukemia. When compared in five solid murine tumors in vivo, both CI-973 and cisplatin were approximately equivalent in activity. In one human colon tumor and one human non-small cell lung carcinoma tested as xenografts in immunodeficient mice, cisplatin and CI-973 were ineffective. In two other human non-small cell lung carcinomas tested in the same fashion, cisplatin did possess activity. CI-973 has entered phase I clinical trials. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink